Benjamin Saylor

New triplet therapy combining belzutifan, pembrolizumab, and lenvatinib shows promising efficacy for advanced clear cell renal cell carcinoma, outperforming other regimens.

New findings reveal that adding durvalumab to chemotherapy enhances survival in muscle-invasive bladder cancer without harming quality of life.

A new treatment regimen for metastatic prostate cancer shows significant reductions in severe adverse events, offering a promising alternative for patients.

The STELLAR-002 study reports promising efficacy and manageable safety for zanzalintinib plus nivolumab in untreated stage 4 RCC patients.

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.

Interim results reveal padeliporfin VTP therapy as a promising, safe treatment for low-grade upper tract urothelial cancer, preserving kidney function.

The ongoing ARASTEP trial evaluates darolutamide plus ADT vs placebo for high-risk prostate cancer biochemical recurrence with PSMA PET-CT-positive lesions, aiming to improve rPFS.

An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.

The EMBARK analysis showed most men regained testosterone after stopping enzalutamide/leuprolide or placebo/leuprolide for prostate cancer with good PSA response, and recovery was common across age groups.

Scott Eggener, MD, gave a talk at the LUGPA annual meeting titled “Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments.”

BCG with gemcitabine was linked to strong early oncological efficacy and safety in previously treated patients with non–muscle-invasive bladder cancer.

Treatment of unresponsive non–muscle-invasive bladder cancer with nadofaragene firadenovec showed a 66% chance of survival and cystectomy-free status at 60 months.

Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.

A review of 50 studies confirmed the safety and efficacy of radium-223 for metastatic castration-resistant prostate cancer treatment.

Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU Cancers Symposium.

Darolutamide with ADT and docetaxel benefits both younger and older patients with metastatic hormone-sensitive prostate cancer, per post hoc analysis.

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic castration-resistant prostate cancer.

In the HERCULES trial, pembrolizumab with platinum-based therapy showed promising safety and efficacy in the treatment of penile squamous cell carcinoma.

Darolutamide delays time to progression from mHSPC to mCRPC vs placebo while also increasing overall survival benefit.

Apalutamide plus androgen deprivation therapy does not appear to negatively impact quality of life in patients with recurrent prostate cancer, while still improving progression-free survival.

Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.

Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.

Regarding safety, the investigators did not observe any grade 3 or 4 adverse events during the study.

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

Real-world data hint that darolutamide may lengthen time to treatment discontinuation and more, in patients with non-metastatic castration-resistant prostate cancer.

Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.

At the final analysis of the ARAMIS study, darolutamide reduced the risk of death by 31% compared with placebo in patients with nonmetastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.